China Biologic Products, Inc. 4
4 · China Biologic Products, Inc. · Filed May 10, 2017
Insider Transaction Report
Form 4
Liu Zhijing CBPO
Vice President
Transactions
- Exercise/Conversion
Stock Option (right to buy)
2017-05-09−1,142→ 0 totalExercise: $9.85From: 2016-09-01Exp: 2022-08-31→ Common Stock (1,142 underlying) - Exercise/Conversion
Common Stock
2017-05-08$9.85/sh+6,358$62,626→ 10,969 total - Sale
Common Stock
2017-05-09$115.40/sh−1,142$131,787→ 4,611 total - Sale
Common Stock
2017-05-08$116.68/sh−6,358$741,851→ 4,611 total - Exercise/Conversion
Common Stock
2017-05-09$9.85/sh+1,142$11,249→ 5,753 total - Exercise/Conversion
Stock Option (right to buy)
2017-05-08−6,358→ 1,142 totalExercise: $9.85From: 2016-09-01Exp: 2022-08-31→ Common Stock (6,358 underlying)
Footnotes (7)
- [F1]Represents 6,358 shares of common stock acquired by the Reporting Person through the exercise of stock options to purchase the Issuer's common stock. See Footnote 7 below for further details on the relevant stock options.
- [F2]Represents 6,358 shares of common stock sold on the open market at a weighted average price of $116.68 per share on May 8, 2017.
- [F3]Represents 1,142 shares of common stock acquired by the Reporting Person through the exercise of stock options to purchase the Issuer's common stock. See Footnote 7 below for further details on the relevant stock options.
- [F4]Represents 1,142 shares of common stock sold on the open market at a weighted average price of $115.40 per share on May 9, 2017.
- [F5]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $116.62 to $116.95, inclusive. The Reporting Person undertakes to provide to any security holders of the Issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Footnote 5.
- [F6]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions in the open market at prices ranging from $115.20 to $115.65, inclusive. The Reporting Person undertakes to provide to any security holders of the Issuer or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this Footnote 6.
- [F7]Represents previously reported stock options to purchase 15,000 shares of the Issuer's common stock, granted to the Reporting Person under the Issuer's 2008 equity incentive plan, pursuant to a stock option agreement dated August 31, 2012. The options were vested annually over a 4-year period in four equal portions, with the initial vesting date being September 1, 2013.